Cryoport supports 779 clinical trials and 22 approved cell and gene therapies as of Q2 2026

Cryoport reported second quarter 2026 results on August 6, 2026, noting the number of commercial cell and gene therapies it supports rose to 22 and its total supported clinical trial count reached 779 worldwide, a net increase of 51 trials over June 30, 2025, with 94 of these trials in Phase 3.¹

On the regulatory front, the company said four of its customers filed Biologics License Applications or Marketing Authorization Applications during the quarter.¹ Among approvals reached in the period, Orca Bio received FDA approval for its cell therapy TREGZI, described by the company as the first and only precision-engineered cell therapy for allogeneic stem cell transplant in adults with hematological malignancies.¹ Separately, Vertex Pharmaceuticals received supplemental FDA approval expanding the label for CASGEVY to patients aged two and older with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia, making it the first approved gene therapy indicated for children as young as two for both conditions.¹

Looking ahead, Cryoport said it anticipates up to 11 additional BLA/MAA filings, five more possible new therapy approvals, and one possible label or geographic expansion approval from its customer base for the rest of 2026.¹ On infrastructure, the company said it is advancing toward launching BioServices operations at its Paris, France supply chain center and continuing progress on a new center in Santa Ana, California, both expected in the fourth quarter of 2026.¹

On finances, Cryoport reported $396.7 million in cash, cash equivalents, and short-term investments as of June 30, 2026,¹ and said it achieved positive adjusted EBITDA in the second quarter, which it called an important milestone on its pathway to sustainable profitability.¹